The purpose of this study was to investigate whether storing mobilized peripheral blood progenitor cell (PBPC) collections overnight before CD34
Autologous hematopoietic progenitor cell transplantation is used increasingly as a form of anti-cancer therapy. 1 In recent years hematopoietic progenitor cells have been collected more often from peripheral blood than bone marrow, since there is more rapid hematopoietic reconstitution. 2 One study has reported a less than one log difference between blood and marrow for number of tumor cells contaminating the graft in lymphoma patients, 3 whereas others report that blood stem cell grafts contain significantly fewer malignant cells than bone marrow. 4, 5 Reinfusion of contaminating neoplastic cells carries the potential of increasing the risk of relapse. [6] [7] [8] [9] Many methods have been developed to eliminate malignant cells in autologous grafts, but such techniques are often associated with substantial loss of hematopoietic stem and committed progenitor cells leading to delayed bone marrow recovery. 10, 11 Alternative approaches include the positive selection of CD34 ϩ cells, which has been reported to reduce the number of contaminating tumor cells 1-3 logs in autografts of patients with non-Hodgkin's lymphoma, 12 multiple myeloma, 13 or breast cancer, 14 yet provides an engraftment rate comparable to unselected autografts. 15, 16 Since the majority of lymphoma cells do not express the CD34 surface marker, CD34 selection of autografts may provide a feasible method to reduce tumor cell contamination and improve the outcome of relapsed lymphoma patients. 17 We previously investigated the use of an immunoaffinity column (CEPRATE SC Stem Cell Concentration System; CellPro, Bothell, WA, USA) for positive selection of CD34 ϩ cells from the peripheral blood of patients with advanced lymphoma. 18 Median times to neutrophil and platelet engraftment were rapid (11 and 13 days, respectively) when the leukapheresis products were processed on the day it was collected. In an effort to optimize usage of the immunoaffinity columns, however, leukapheresis products for 11 patients were stored overnight at 4°C prior to processing. Although overnight storage did not affect neutrophil engraftment (median 11 days, range 11-14 days), platelet engraftment was significantly delayed (median 28.5 days, range 12-39, P ϭ 0.02). This effect was observed even in patients who received more than 2.0 × 10 6 CD34 ϩ cells/kg. Reduction of tumor cell contamination in autografts may benefit patients undergoing autologous stem cell transplantation (fewer or no tumor cells for re-infusion). However, currently available methods can be costly. Based on the previous, nonrandomized study, 19 we concluded that the effects of overnight storage should be further evaluated as a means to reduce the overall cost of purging an autograft. We designed a prospective, randomized study to investigate whether overnight storage has an effect on the CD34 ϩ selection procedure and platelet recovery.
Materials and methods

Study population
Sixty-nine patients were registered between November 1996 and January 1998. Patients (age 14-65 years) with a histologic diagnosis of Hodgkin's disease or non-Hodgkin's lymphoma with relapsed, primary refractory (inductionfailure), or high-risk of disease recurrence, 20 who were eligible for high-dose cytotoxic therapy, were considered for entry to this multi-center study. The study was conducted under an Investigational Device Exemption from the FDA and approved by the Institutional Review Boards at the University Hospitals of Cleveland, Cleveland, OH, Hackensack Medical Center, Hackensack, NJ, and University of North Carolina, Chapel Hill, NC. All patients gave written informed consent to participate.
Patients were required to have an ECOG status of 0 or 1 and were required to have adequate visceral organ function including: left ventricular ejection fraction at least 45% of predicted, no uncontrolled hypertension, FEV 1 and DLCO Ͼ50% of predicted, actual or calculated creatinine clearance Ͼ60 ml/min, SGOT and SGPT Ͻ3 times normal, and no severe endocrine or neurologic disorders. At the start of mobilization therapy, a blood neutrophil count Ͼ1200 × 10 9 /l and platelet count Ͼ100 000 × 10 9 /l were required.
Patients were excluded if they had: received more than two different prior chemotherapy regimens; prior radiation in excess of defined amounts (1500-4000 cGy depending upon site); cumulative exposure to carmustine greater than 200 mg/m 2 ; bleomycin more than 100 units/m 2 ; doxorubicin in excess of 550 mg/mg 2 ; evidence of active infection; or a history of another malignant disease within the past 5 years. Patients were not excluded for evidence of tumor on routine histologic staining of bilateral paraffin-embedded posterior iliac crest bone marrow biopsies.
Mobilization and collection of PBPC
Patients began peripheral blood progenitor cell (PBPC) mobilization after registration using a regimen reported previously. 18 The mobilization regimen consisted of cyclophosphamide (4.0 g/m 2 ) intravenously over 3-6 h on the first day of mobilization along with mesna 3.0 g/m 2 within the cyclophosphamide dosing bag, then 500 mg every 3 h by mouth or by vein for eight doses. Prednisone (2 mg/kg/day) was given orally for the first 4 days of mobilization. Neupogen (G-CSF) (Amgen, Thousand Oaks, CA, USA) (10 g/kg/day) was given subcutaneously beginning between 36 and 48 h after the completion of cyclophosphamide therapy and continuing until the last day of leukapheresis or until the WBC was у75 000 × 10 9 /l. Leukapheresis was initiated when the absolute neutrophil count (ANC) was Ͼ1000 × 10 9 /l and platelet count was Ͼ30 000 × 10 9 /l after the post-chemotherapy nadir (usually 12-15 days after cyclophosphamide therapy). PBPC were collected using standard leukapheresis procedures (COBE SPECTRA, Lakewood, CO, USA; or a similar machine). The target for the leukapheresis was to process 10-15 l of whole blood (or 3 patient blood volumes) and the procedure was continued for a maximum of 4 days until a combined minimum collection of at least 10.0 × 10 8 mononuclear cells/kg was achieved. The ultimate goal was to collect a combined minimum of 2.0 × 10 6 total CD34 ϩ -enriched cells/kg patient weight after using the CEPRATE SC System. If either of these minimum numbers were not reached in four or fewer leukaphereses, the patient was taken off the study; additional leukaphereses or alternative treatments were to be determined by the site investigator and the principal investigator.
Overnight storage
Patients were randomized at the initiation of the leukapheresis procedures to have the PBPC collection processed immediately or after overnight storage. Leukapheresis products obtained from patients in the overnight storage group were stored overnight at 4°C, while leukapheresis products procured from patients in the immediate arm were processed using the CEPRATE SC System the same day. All subsequent collections were processed in the same fashion. None of the leukapheresis products were combined with the next leukapheresis product prior to CD34 selection.
Positive selection of CD34
ϩ cells from mobilized PBPC Harvested mononuclear cells from each leukapheresis collection were prepared and selected for CD34 ϩ cells using the CEPRATE SC System as described by the manufacturer. Adsorbed CD34 ϩ cells were resuspended at 2 × 10 7 cells/ml and frozen using a controlled-rate liquid nitrogen freezer in the presence of 7.5% (final concentration) dimethyl sulfoxide (DMSO; Sigma, St Louis, MO, USA). Aliquots of the PBPCs, unprocessed and enriched for CD34 ϩ cells, and non-target (unbound) cells were analyzed for progenitor cell content by clonogenic assays and for CD34 ϩ cells using flow cytometry.
CD34 ϩ cell enumeration and flow cytometry
Each site used a modification of a protocol for flow cytometry for enumerating CD34 ϩ cell number, 21 and a representative flow cytometry plot is shown ( Figure 1 propidium iodide-negative events. For each sample 250 000 events were acquired as list mode data using CellQuest software (Becton Dickinson). Percent CD34 ϩ cells was determined by analyzing the entire CD45-positive (dim and bright) population on a CD34-PE FL2-height (X) vs SSCheight (Y) dot plot. Background fluorescence activity was determined by isotype antibody and subtracted from each measurement. The total CD34 ϩ cells were calculated by multiplying the percentage of CD34 ϩ cells by the total number of nucleated cells in the pheresis product, which was the product of the white blood cell (WBC) count from a WBC enumerator such as a Coulter Epics-Profile II (Coulter, Miami, FL, USA) or Sysmex-100 (TOA Medical Electronics, Kobe, Japan) hematology analyzer and the volume of the pheresis product. WBC count was determined before and after overnight storage (R 2 correlation coefficient ϭ 0.69). WBC obtained after overnight storage was used for this calculation.
High-dose chemotherapy and stem cell support
The protocol required administration of a high-dose BCNU-containing (carmustine) chemotherapy regimen. Each center used one of three preparative regimens: carmustine/etopside/cisplatin 22 was used at Case Western Reserve University, carmustine/etoposide/cytarabine/cyclophosphamide 23 was employed at Hackensack Medical
Bone Marrow Transplantation
Center, and carmustine/etoposide/cytarabine/melphalan 24 was used by the University of North Carolina. Involvedfield radiation therapy was given to active/previously bulky (Ͼ5 cm) tumors as 1500 to 2000 cGy in 200 cGy fractions in selected patients. All days referred to herein were calculated from the day of CD34 ϩ cell infusion (day 0). Starting the first day after PBPC infusion (day 1), G-CSF was administered subcutaneously in single or divided injections at a dose of 10 g/kg/day until the patient had an ANC у1000 × 10 9 /l for 3 consecutive days. Platelet engraftment was defined as the first of 7 consecutive days that platelet count was у20 000 × 10 9 /l without transfusion support for low counts and no platelet count Ͻ20 000 × 10 9 /l for 6 days after that day.
Supportive care
All patients received a multi-lumen, indwelling central venous pheresis catheter and were cared for in single hospital rooms. Antibiotics were given prophylactically or empirically for fever and neutropenia according to the guidelines for each participating institution, and all patients were supported with irradiated blood components. Irradiated, packed RBC transfusions were given in an attempt to keep the Hct Ͼ25%, and irradiated platelet transfusions were given for platelet counts less than 10 000- 20 000 × 10 9 /l or bleeding complications. CMV-negativeor leukocyte-depleted filtered blood products were given to CMV-seronegative patients.
Statistical methods
The primary in vivo outcome variable for comparing the study groups was time to platelet engraftment. One interim analysis was planned when half the patients (20 per group) were enrolled; a stopping rule devised by Peto et al 25 based on an approximate group sequential plan with one interim and one final analysis was used to provide a statistical basis for early termination of the trial. The trial would be stopped at the interim analysis if the difference between study groups (time to platelet engraftment) was statistically significant using a significance level of 0.001. Unless otherwise stated, the statistical analyses presented are for the patients who received an autograft using CD34 ϩ selected cells only. Missing data were not estimated or carried forward in any statistical analyses. The analysis of the time to platelet engraftment used a one-sided test. The sample size calculations assumed that time to platelet engraftment data had an exponential distribution, and that a difference of 10 days or more was assumed to be a clinically meaningful difference in time to platelet engraftment (power 0.80). For the additional endpoints the between-group comparisons used two-tailed test procedures. A significance level of 0.05 (␣ ϭ 0.05) was used for all analyses. The null hypothesis of interest for all analyses was that there was no difference between the study groups. The study groups were compared with respect to age and the processing data using two-sample t-tests. The Wilcoxon rank sum test was used to compare the groups with respect to the leukapheresis data. The Cox proportional hazards regression model (Wald statistic) was used to analyze the engraftment data. Fisher's exact test was used to analyze gender and performance status. + cells are the results of the total of all leukaphereses administered to the patients. Results for purity, enrichment and yield are presented for each product that was processed. Due to missing data the n for some cells does not equal the number of patients or the number of leukaphereses. *t-test.
Results
Patient characteristics
The clinical characteristics of the study patients who were included in the analyses are summarized in Table 1 . There were no significant differences between the study groups in terms of gender, age, or ECOG performance status. One patient died prior to mobilization, and thus, 68 proceeded with mobilization and leukaphereses. At initiation of the PBPC collection, patients were randomized at one center (Ireland Cancer Center) using a sealed assignment. Fifteen of the 68 patients were excluded from the analysis: three were not transplanted (one was found to have progressive disease prior to transplant and two died prior to transplant) and 12 patients later underwent autotransplant using unselected cells alone, or a combination of selected and unselected cells since they had less than 2.0 × 10 6 CD34 ϩ cells/kg.
Characterization of peripheral blood CD34 ϩ cells and results of positive selection
Seventy-four leukapheresis products (collected from 30 patients) processed immediately after collection were compared with 62 leukapheresis products (obtained from 23 patients) which were processed after being stored overnight. After storage and before selection, the number of mononuclear cells, percent CD34
ϩ cells, and total number of CD34 ϩ cells in the product did not differ significantly between those patients whose products were processed immediately vs those whose products were stored overnight Figure 3 Proportion of patients recovering neutrophil count vs days after PBPC re-infusion. Effect of overnight storage on time to neutrophil count recovery (у500 × 10 9 /l). Neutrophil count reached 500 × 10 9 /l in a median of 10.5 days (range 9-14) after immediate processing compared to 11 days (range 9-16) after overnight storage (P = 0.421, Cox proportional hazards regression model).
( Table 2 , P у 0.659). After selection, the number of mononuclear cells, percent CD34
ϩ cells, the total number of CD34 ϩ cells in the product, as well as the enrichment and yield of the selection process, were similar between the arms (Table 2) . Furthermore, the percentage of patients who achieved the minimum target of 2.0 × 10 6 CD34 ϩ cells in only one or two leukaphereses did not differ statistically between the arms (P ϭ 0.373) (Figure 2 ).
Hematopoietic engraftment
Hematopoietic engraftment did not differ significantly between the treatment arms ( Figures 3 and 4) . The ANC reached 500 × 10 9 /l in a median of 10.5 days (range 9-14) in the immediate processing arm compared to 11 days (range [9] [10] [11] [12] [13] [14] [15] [16] /l without the need for a transfusion. The group assigned to overnight storage had a median day of platelet recovery of 13 days (range 7-43 days) compared to 13.5 days (range 8-53 days) in the group who underwent immediate processing (P = 0.933, Cox proportional hazards regression model).
Table 3
Effect of overnight storage of PBPC collections on engraftment after re-infusion
Median day neutrophils 10.5 11 0.421 у500 × 10 9 /l (9-14) (9-16) Median day platelets 13.5 13 0.933 у20 000 × 10 9 /l (8-53) (7-43) a Platelet recovery was defined as the first of 7 consecutive days of sustained platelet count у20000 × 10 9 /l without the need for platelet transfusions. *Cox proportional hazards regression model (Wald statistic). Table 3 ). Delayed platelet engraftment (over 21 days) was observed in seven patients: four whose product was processed immediately and three whose product was stored overnight. In addition, there was one patient in the overnight storage arm who had a censored time to platelet engraftment since death occurred on day 30 which was prior to engraftment.
Four patients, two in each treatment arm, were given high-dose chemotherapy and underwent re-infusion with a CD34 ϩ selected cell dose less than 2.0 × 10 6 CD34 ϩ cells/kg. Neutrophil engraftment occurred by day 12 and platelet engraftment on day 14 for two of these patients, one in each arm. A third patient, whose products were processed immediately, experienced neutrophil and platelet recovery on days 21 and 38, respectively. The remaining patient died prior to engraftment, as described above. There were no significant differences between the study groups in the number of platelet transfusions administered from day 0 to day 100 (P ϭ 0.704) (mean ϭ 6.6 after immediate processing vs mean ϭ 5.1 after overnight store). Furthermore, the arms were comparable in the percent of patients with platelet transfusions after platelet recovery 
Excluded patients
Fifteen patients were excluded from the primary analyses. Three patients did not undergo transplant: two subjects died and one was noted to have disease progression before the planned transplant. Twelve patients (all non-Hodgkin's lymphoma) were excluded (four in the immediate arm and eight in the overnight storage arm) because they did not reach the target criteria of having at least 2.0 × 10 6 CD34 ϩ cells/kg either available for selection, or attaining this number after the enrichment procedure, despite undergoing up to four leukapheresis procedures. These patients, however, received a transplant using either unselected cells alone, or a combination of selected and unselected cells.
Discussion
High-dose chemotherapy and stem cell transplantation have significantly improved the outcome for patients with relapsed lymphoma. 26 More than half of the patients, however, will eventually die of their disease. While most relapses occur due to ineffectiveness of the preparative regimen in eradicating tumor in the patient, re-infusion of tumor cells in the autograft also may contribute to disease recurrence. [6] [7] [8] [9] Although direct evidence is lacking, several observations indirectly imply that contaminating tumor cells contribute to relapse in patients with lymphoma. 5, 17 Clinical efficacy of purging has been difficult to elucidate in leukemias and lymphomas due to the positive relationship between the patient's tumor burden and the degree of tumor contamination in the hematopoietic cell harvest and the biologic differences of tumor cell susceptibility to purging agents. 27, 28 Nonetheless, purging of autologous grafts for lymphoma is actively pursued since more than half of patients with relapsed lymphoma will die of their disease. In order to improve the fate of the relapsed lymphoma patients and study the role of purging in overall outcome, it is important to develop effective and relatively simple means of tumor cell purging for PBPC collections with preservation of rapid engraftment capacity, especially if the costs can be minimized.
We reported previously the successful use of autologous CD34 ϩ -enriched PBPC for hematopoietic reconstitution after myeloablative chemotherapy in patients with advanced lymphoma. 18 The use of PBPC enriched for CD34 ϩ cells using the CEPRATE SC System resulted in rapid recovery of hematopoietic function at a tempo similar to transplants in which unselected PBPC were given. Efforts to reduce manpower costs and the number of immunoaffinity columns used per patient, however, were hampered by data indicating that overnight storage of the product before CD34 ϩ cell selection appeared to result in a lower cell yield (mean 2.4-fold fewer CD34 ϩ cells reinfused) as well as an increase in the time to platelet engraftment. 18 These results, however, were inconsistent with previous reports which have indicated that storage of PBPC for periods up to 5 days has minimal effect on cell count, cell viability, and CFU-GM. [29] [30] [31] [32] More importantly, other investigators have reported that overnight storage prior to processing had no effect on platelet recovery after transplant. 33, 34 We attribute the differences in these two reports to the fact that our initial trial was not randomized and patient characteristics were not balanced. Storage of the PBPC product overnight prior to processing allows schedule flexibility as well as the opportunity to combine and process cell collections obtained over 2 days using a single immunoaffinity column.
We designed this unique, prospective, randomized study to systematically investigate whether overnight storage of PBPC collections had any negative effect on column performance or engraftment after re-infusion. We demonstrated that overnight storage did not affect the cell yield after the selection procedure. Furthermore, overnight storage did not adversely affect neutrophil or platelet engraftment after high-dose chemotherapy. This trial, however, was designed for equivalence using a clinically-meaningful endpoint, ie time to platelet recovery would not differ by more than 10 days between the two arms. Given the study design and small sample size, we could not detect a shorter delay in recovery between arms. Furthermore, CD34 enumeration was conducted at each center. We cannot discount the possibility that small differences in technique contributed to variation. Each center, however, was particularly adept at performing CD34 analyses, utilized the ISHAGE method for validation of CD34 enumeration, and patients underwent block randomization at each center, offsetting differences in the overnight storage vs the immediate storage group. 35 Finally, the endpoint of the trial was in vivo engraftment, not CD34 content of collections, which did not differ between the two patient groups.
In our previous non-randomized study, we did not identify a correlation between the number of CD34 ϩ cells infused and platelet engraftment in patients whose collections were stored overnight. 18 In this current randomized study, only seven patients, evenly distributed between the two groups of the study and among the three centers, experienced a delay in platelet engraftment. We again were unable to identify why this group had a longer time to engraftment, since these patients did not differ from the others regarding previous chemo-radiation therapy history or number of CD34 ϩ cells re-infused. Twelve patients excluded from the analysis clearly were 'poor mobilizers', a common problem noted in lymphoma patients. [36] [37] [38] This group, however, subsequently underwent high-dose chemotherapy and autotransplant using either unselected PBPC or a combination of selected and unselected cells.
In routine clinical practice mobilization of autologous PBPC usually requires that more than one apheresis procedure be performed for collecting an adequate quantity of CD34 ϩ cells to ensure prompt and sustained hematopoietic recovery after re-infusion. As the number of apheresis procedures is increased, however, the incidence of tumor cell contamination rises. 39, 40 Strategies to reduce or eliminate tumor cell contamination, which include the use of CD34 ϩ selection devices, will be limited by their high cost. The results of this study demonstrate that storage of PBPC col-lections at 4°C for 24 h does not have a negative impact on the CD34 selection process, nor does it adversely effect the ability of the CD34-enriched PBPC to provide rapid hematopoietic recovery. The capacity to hold PBPC collections overnight will result in reduced manpower and costs without an adverse impact on PBPC engraftment. This observation may allow expanded use of this technology and permit further study of the effect of tumor contamination on cancer recurrence in the autologous PBPC transplant setting.
